Barrett's esophagus screening: Difference between revisions
Jump to navigation
Jump to search
Pal Manickam (talk | contribs) |
Pal Manickam (talk | contribs) |
||
| Line 12: | Line 12: | ||
* Strong recommendation, low-quality evidence: | * Strong recommendation, low-quality evidence: | ||
# Recommend against screening general population with GERD and no risk factors.<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |}}</ref> | # Recommend against screening general population with GERD and no risk factors.<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |}}</ref> | ||
==Surveillance== | |||
Weak recommendation, moderate-quality evidence: Endoscopic surveillance in patients with Barrett's esophagus | |||
The following intervals are recommended: | |||
* No dysplasia: 3–5 years. | |||
* Low-grade dysplasia: 6–12 months. | |||
* High-grade dysplasia in the absence of eradication therapy: 3 months.<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |pmid=21376940 |doi=10.1053/j.gastro.2011.01.030 |url=}}</ref> | |||
==References== | ==References== | ||
Revision as of 01:00, 24 December 2012
|
Barrett's Esophagus Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Barrett's esophagus screening On the Web |
|
American Roentgen Ray Society Images of Barrett's esophagus screening |
|
Risk calculators and risk factors for Barrett's esophagus screening |
Barret's esophagus is a major risk factor for development of esophageal adenocarcinoma. After diagnosis, regular surveillance is needed based on the grade of dyaplasia.
Overview
- Weak recommendation, moderate-quality evidence: screening in patients with multiple risk factors for esophageal adenocarcinoma:
- Age: > 50 years old
- Sex: male
- Race: white
- Other: chronic GERD, hiatal hernia, elevated BMI (body mass index),and intraabdominal distribution of body fat.
- Strong recommendation, low-quality evidence:
- Recommend against screening general population with GERD and no risk factors.[1]
Surveillance
Weak recommendation, moderate-quality evidence: Endoscopic surveillance in patients with Barrett's esophagus The following intervals are recommended:
- No dysplasia: 3–5 years.
- Low-grade dysplasia: 6–12 months.
- High-grade dysplasia in the absence of eradication therapy: 3 months.[1]